Merck wins 1st FDA approval for Keytruda
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...
Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...
Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...
Zacks.com on MSN2d
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback